TNL MEDIAGENE
TNMG · NASDAQ
Updated at 2026-10-13 13:20:56
- Today's High
- --
- Today’s Low
- --
%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23150%3B%26%23135%3B%26%23230%3B%26%23161%3B%26%23163%3B%26%23230%3B%26%23154%3B%26%23151%3B%26%23232%3B%26%23167%3B%26%23146%3B%22%20d%3D%22M48.3363%2013.4132H60.2082L46.795%205.72205e-06V11.8719C46.795%2012.7231%2047.4851%2013.4132%2048.3363%2013.4132Z%22%20fill%3D%22var(--fill-0%2C%20%23474741)%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23148%3B%26%23190%3B%26%23229%3B%26%23164%3B%26%23167%3B%26%23233%3B%26%23149%3B%26%23156%3B%22%20fill-rule%3D%22evenodd%22%20clip-rule%3D%22evenodd%22%20d%3D%22M11.3812%2020.3725C16.7977%2014.9559%2025.5803%2014.9559%2030.9969%2020.3725C36.413%2025.789%2036.4131%2034.5707%2030.9969%2039.9872C26.0109%2044.973%2018.1729%2045.3699%2012.7335%2041.1769L2.54298%2051.3684L0%2048.8254L10.1915%2038.6329C5.99993%2033.1937%206.39609%2025.3579%2011.3812%2020.3725ZM28.4539%2022.9155C24.4418%2018.9033%2017.9363%2018.9033%2013.9241%2022.9155C9.91245%2026.9275%209.91241%2033.4322%2013.9241%2037.4442C17.9362%2041.4562%2024.4418%2041.4562%2028.4539%2037.4442C32.4656%2033.4322%2032.4656%2026.9275%2028.4539%2022.9155Z%22%20fill%3D%22var(--fill-0%2C%20%235D5D56)%22%2F%3E%0A%3C%2Fg%3E%0A%20%20%3C%2Fsvg%3E%0A%3C%2Fsvg%3E%0A)
Candlestick trends are for reference. Refer to the trading page for actual data.
Key Statistics
- Previous Open
- $3.75
- Previous Close
- $3.66
- Volume
- 24.54K
- Market Cap
- $2.78M
- P/E Ratio
- --
- EPS
- $-29.47
Previous Day Range
52-Week Range
Company Overview
- Sector
- COMMUNICATION SERVICES
- Industry
- Media
- Sub-industry
- PUBLISHING
- Headquarters
- 23-2 MARUYAMACHO, TOKYO, JAPAN, 150-0044
- Country
- TW
- Listing Date
- 2024-12-06
- Fiscal Year End
- December
- Shares Outstanding
- 6.31M
- CIK
- 0002013186
- Website
- www.tnlmediagene.com
TNL Mediagene Ordinary Shares is an innovative biopharmaceutical firm focused on developing and commercializing cutting-edge therapies for oncology and autoimmune disorders. The company boasts a strong pipeline driven by advanced technologies and strategic collaborations, positioning it for significant growth in the evolving healthcare market. TNL Mediagene's commitment to scientific excellence and patient-centered solutions reinforces its aim to enhance patient outcomes while addressing critical health challenges, thereby establishing itself as a notable entity within the biopharmaceutical landscape.
Financial Metrics
Revenue
2026-03-31
$23.23M
2025-06-30
$21.78M
2025-03-31
$10.89M
2024-06-30
$20.6M
Operating Expenses
2026-03-31
$11.72M
2025-06-30
$12.62M
2025-03-31
$6.31M
2024-06-30
$13.76M
Net Income
2026-03-31
-$40.22M
2025-06-30
-$4.32M
2025-03-31
-$2.16M
2024-06-30
-$5.92M
Net Profit Margin
2026-03-31
-173.13%
2025-06-30
-19.83%
2025-03-31
-19.83%
2024-06-30
-28.73%
Earnings Per Share
2026-03-31
--
2025-06-30
--
2025-03-31
--
2024-06-30
--
Earnings Before Interest, Taxes, Depreciation, and Amortization
2026-03-31
-$3.07M
2025-06-30
-$4.01M
2025-03-31
-$2M
2024-06-30
-$4.08M
Effective Tax Rate
2026-03-31
11.04%
2025-06-30
1.02%
2025-03-31
1.02%
2024-06-30
-1%
| Item | 2026-03-31 | 2025-06-30 | 2025-03-31 | 2024-06-30 |
|---|---|---|---|---|
| Revenue | $23.23M | $21.78M | $10.89M | $20.6M |
| Operating Expenses | $11.72M | $12.62M | $6.31M | $13.76M |
| Net Income | -$40.22M | -$4.32M | -$2.16M | -$5.92M |
| Net Profit Margin | -173.13% | -19.83% | -19.83% | -28.73% |
| Earnings Per Share | -- | -- | -- | -- |
| Earnings Before Interest, Taxes, Depreciation, and Amortization | -$3.07M | -$4.01M | -$2M | -$4.08M |
| Effective Tax Rate | 11.04% | 1.02% | 1.02% | -1% |
FAQs
Risk Warning
Stock prices can be highly volatile and may rise or fall sharply in a short period. Digital asset and derivative products involve additional risks such as leverage and liquidity. Content on this page is for reference only and does not constitute investment advice. Product availability and access may vary by region and applicable regulations.